Related Articles
TRANSCRIPTIONAL ANTAGONISM BETWEEN P53 AND SV40 T-ANTIGEN
The human oncoprotein MDM2 uses distinct strategies to inhibit transcriptional activation mediated by the wild-type p53 and its tumor-derived mutants
Differential modulatation of cellular and viral promoters by p73 and p53
MDM2 oncogene as a target for cancer therapy: An antisense approach.
Recombinant human MDM2 oncoprotein shows sequence composition selectivity for binding to both RNA and DNA